Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal…
- Trial name
- NCT00398879
- Testing
- Perifosine, Capecitabine
- Where
- 49 sites in United States
- Volunteers
- 381 people
- Sponsor
- AEterna Zentaris
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
Cancer of Rectum, Cancer of Pancreas
LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS
This is a prospective, observational, multicenter cohort study. Our main objective is to to evaluate the use of CTCs and ctDNA with prognostic factors in locally advanced rectal tumors treated with total neoadjuvant therapy…
- Conditions
- Cancer of Rectum, Cancer of Pancreas, Cancer of Stomach
- Trial name
- BLENTI (NCT06940778)
- Testing
- No Interventions
- Where
- Brazil
- Volunteers
- 273 people
- Sponsor
- Hospital do Coracao
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Colorectal Neoplasms, Precancerous Conditions
Liquid Biopsy in Early Colorectal Lesions
Early colorectal cancer screening increasingly detects small superficial colonic lesions, but current diagnostic tools still struggle to distinguish benign from malignant lesions and to assess lymph node risk.
- Conditions
- Colorectal Neoplasms, Precancerous Conditions, Adenocarcinoma of the Colon
- Trial name
- FECCO-BioBank (NCT07319104)
- Testing
- Venous blood sampling
- Where
- 12 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Montpellier
Colorectal Cancer
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
- Trial name
- COLOCROSS (NCT00905047)
- Testing
- XELODA, TEGAFUR URACIL - FOLINIC ACID
- Where
- 13 sites in France
- Volunteers
- 89 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced/Metastatic Colorectal Cancer
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC.
- Trial name
- NCT06322563
- Testing
- LTC004+regorafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Liver Metastases
SAMe in Prevention of Oxaliplatin-associated Liver Injury
This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury
- Trial name
- NCT06258525
- Testing
- Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Colorectal Cancer, Diarrhea
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084721
- Testing
- celecoxib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer, Metastatic Cancer
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00083616
- Testing
- Panitumumab
- Volunteers
- 185 people
- Sponsor
- Amgen
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Colon Cancer Liver Metastasis
Perioperative Treatment of Resectable Liver Metastases
This randomized, controlled, multicenter, non-comparative phase II trial compares an intensified perioperative treatment of patients with resectable synchronous or metachronous colorectal liver metastases to primary surgery and…
- Trial name
- PERIMAX (NCT01540435)
- Testing
- Bevacizumab
- Sponsor
- University of Regensburg
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Recurrent Breast Cancer, Recurrent Colon Cancer
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors.
- Conditions
- Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer
- Trial name
- NCT01987726
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.